Oncolytic Virotherapy Development for Combination Therapy with Adoptive T Cell Therapy
Oncolytic viruses represent a new class of therapeutic agents that promote anti-tumor responses through a dual mechanism of action that is dependent on selective tumor cell killing and the induction of systemic anti-tumor immunity. As a standalone therapy, the effects of OVs are possibly restricted by the tumor microenvironment, host-mounted anti-viral responses as well as pre-existing neutralizing antibodies. It was demonstrated that oncolytic viruses could be usefully integrated into tumor immunotherapies, as they target multiple steps within the cancer–immunity cycle. Creative Biolabs is a world-renowned service developer and provider of oncolytic virotherapy and cancer immunotherapy, and our scientists focus on applying outstanding technologies to the discovery and development of potential therapeutic approaches.
Immunotherapy is a type of cancer treatment that boosts the body's natural defenses to fight cancer. Adoptive cell transfer (ACT) therapy is a treatment that attempts to fight cancer by boost the natural ability of your T cells. OVs can facilitate ACT by conditioning both the systemic immune system and local tumor microenvironment (TME) to better support T cell recruitment and effector function. It was shown that the combination therapy was far more effective than either monotherapy owing to improved T cell effector function. Creative Biolabs have developed a thorough immunotherapy platform for combining oncolytic virotherapy with adoptive cell transfer therapy specific to various types of disease which are potentially suitable to our clients' demands.
Our combination of oncolytic virotherapy and ACT therapy services include but not limited to:
- Tumor-Infiltrating Lymphocyte Therapy (TIL)
Tumor-infiltrating lymphocyte therapy has been demonstrated to have durable clinical responses in patients with metastatic melanoma and is now being increasingly applied to treat other solid tumors, including head and neck squamous cell carcinoma, cervical cancer, breast cancer, and lung cancer. In TIL therapy, T cells are cultured from autologous tumors and expanded in vitro before reinfusion into the patient. Pre-treatment of established tumors with OVs may change the local tumor microenvironment to improve T cell recruitment and effector function.
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
Chimeric antigen receptor T cells are genetically modified T cells that express CARs, fusion proteins that incorporate antigen recognition moieties and T-cell activation domains. CAR-T therapy has the capacity to be engineered to target virtually any tumor associated antigen. Compared with single agents, the combination of OVs and CAR T cells resulted in improved control of tumor growth and greatly increased survival.
- T-Cell Receptor-Engineered T Cells Therapy (TCR-T)
T-cell receptor-engineered T cells therapy uses the transfer of cancer-specific T cell receptor (TCR) genes into T cells that can be isolated from the patients' peripheral blood, which can be effective to fight against large and long-established solid tumor. OVs has the ability to release TAAs to broaden and amplify T cell responses.
- Dendritic Cell and Cytokine-Induced Killer Cell Immunotherapy (DC-CIK)
DCs are the most potent antigen-presenting cells which are essential in CIK activation and can remarkably enhance the cytotoxicity of CIK cells. Several research reports have shown that the combination of OVs and CIK/DC-CIK immunotherapy and conventional therapy is safe and markedly prolongs survival time, enhances immune function and improves the treatment efficacy.
- Assay Models in Vivo
We provide multiple types of animal models which have severe immune system function defects that can be used for xenograft transplantation studies.
Non-Obese Diabetic mice (NOD)
NOD-SCID-IL2rg mice (NSG)
NOD-Prkdc-IL2rg mice (NDG)
NOD/ShiLtJNju-Prkdc-IL2RG mice (NCG)
NOD/Shi-scid-IL-2R mice (NOG)
Creative Biolabs has long devoted to the development and application of oncolytic virotherapy for combination adoptive T cell therapy. Based on advanced technologies and years of experience in cancer therapy study, we provide high-quality one-stop combination therapy development services for clients worldwide. We are able to develop specific oncolytic viruses to combine with different types of adoptive T cell therapy to meet your research demands both in vitro and in vivo. Please feel free to contact us for more details and we are pleased to offer you the best services.
References:
- Radvanyi, L. G. (2015). Tumor-infiltrating lymphocyte therapy: addressing prevailing questions. The Cancer Journal, 21(6), 450-464.
- Kato, T., Matsuda, T., Ikeda, Y., Park, J. H., Leisegang, M., Yoshimura, S., ... & Hasegawa, K. (2018). Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget, 9(13), 11009.
- Liu, Y., Mu, Y., Zhang, A., Ren, S., Wang, W., Xie, J., ... & Zhou, C. (2017). Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis. OncoTargets and therapy, 10, 1897.